XCR Diagnostics Announces the Appointment of J. Chuck Morrison to Its Board of Directors

SALT LAKE CITY–(BUSINESS WIRE)–XCR Diagnostics announced today that it has appointed Chuck Morrison, a seasoned medical diagnostics expert, to its Board of Directors.

Morrison is a global business development executive with a successful track record negotiating and executing acquisitions, licensing deals, partnerships and distribution deals with 40 years of experience in Life Science, Biotechnology and Diagnostics.

Morrison was instrumental in Meridian Bioscience’s 2019 acquisition of GenePOC Inc. He served as a director for GenePOC and led the negotiation with Meridian Biosciences. Prior to that effort, he was the director of business development at PerkinElmer, managing numerous acquisitions driving the strategic growth of PerkinElmer’s Life Science and Diagnostic businesses. Morrison holds a BA in Chemistry from the College of the Holy Cross and an MBA in Finance and Marketing from Boston University.

“We are pleased to welcome Chuck to our Board of Directors at this important next stage of XCR’s evolution,” stated Mark Powelson, XCR Diagnostics CEO. “As a highly respected medical diagnostics executive, Chuck is a welcome addition to advancing Xtreme Chain Reaction (XCR®) and our simple, affordable testing device for worldwide near patient diagnostic testing.”

Morrison stated: “I am excited about joining the XCR Board. I look forward to working alongside my fellow board members and company’s management to advance truly innovative molecular technology to benefit patients worldwide.”

About XCR Diagnostics, Inc.

XCR Diagnostics Inc. is an early stage nucleic acid system company advancing near patient portable molecular diagnostics instrumentation, sample delivery systems, amplification, detection and analysis to the diagnostic markets, domestically and internationally. The company is positioned to provide the first sub-10-minute to a negative test result to the market, meaning a positive result could be as rapid as seven minutes. The combination of small portable Nucleic Acid Testing System (Pyramid) platforms and revolutionary molecular reagents enables XCR Diagnostics to dramatically trim test times and reduce healthcare costs, with a vision to deliver hyper-accurate molecular diagnostics testing near patient and central laboratory. To learn more about XCR Diagnostics, please visit us at www.xcrdiagnostics.com.


Mark Powelson

XCR Diagnostics, Inc.


error: Content is protected !!